In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with ...

The annualized rate of severe asthma exacerbations was 0.46 (95% confidence interval [CI], 0.39 to 0.53) among patients assigned to 200 mg of dupilumab every 2 weeks and 0.87 (95% CI, 0.72 to 1.05 ...

Children with uncontrolled, moderate to severe asthma used dupilumab or placebo for 52 weeks. The treatment group had significant decreases in annualized exacerbation rates compared with the ...

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine , 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 Cite This Page : ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab significantly reduced asthma exacerbations and improved lung function within 2 weeks in children ...

Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high daily OCS doses at ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma. Patients with type 2 inflammatory asthma, with and without evidence of allergic asthma ...

Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE ...

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.